Baseline demographic and clinical characteristics
| Variables | Values (n = 73) |
|---|---|
| Age at diagnosis, n, years (SD) | 70*, 43.9 (10.1) |
| Disease duration, n, years (SD) | 59*, 15.0 (7.9) |
| Age at initiation of SB5, n, years (SD) | 73, 59.6 (9.8) |
| Gender, n (%) | |
| 54 (74.0) |
| 19 (26.0) |
| Body mass index, n (%) | |
| 1 (1.4) |
| 59 (80.8) |
| 13 (17.8) |
| Work status at SB5 initiation, n (%) | |
| 26 (35.6) |
| 10 (13.7) |
| 37 (50.7) |
| Tobacco use at SB5 initiation, n (%) | |
| 9 (12.3) |
| 20 (27.4) |
| 44 (60.3) |
| Clinical status based on disease activity score, n (%, n = 41) | |
| 26 (63.4) |
| 5 (12.2) |
| 10 (24.4) |
| 0 |
| Concomitant therapy received by > 5% of the total patient population, n (%) | |
| 41 (56.2) |
| 9 (12.3) |
| 22 (30.1) |
| 7 (9.6) |
| 9 (12.3) |
| 5 (6.8) |
| 6 (8.2) |
| Biologic therapy prior to adalimumab, n (%) | 16 (21.9) |
| Received information on self-administration of SB5, n (%) | 66 (90.4) |
| Aware that SB5 should be removed from the refrigerator 30 min prior to injection, n (%) | 63 (86.3) |
| Aware that SB5 can be stored unrefrigerated < 25ºC for up to 28 days, n (%) | 51 (69.9) |
* n differs from overall n due to incomplete data capture. HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A; SD: standard deviation